共 301 条
[1]
Gutierrez C(2011)HER2: biology, detection, and clinical implications Arch Pathol Lab Med 135 55-62
[2]
Schiff R(2006)Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809-820
[3]
Joensuu H(2007)2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29-36
[4]
Kellokumpu-Lehtinen PL(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2 N Engl J Med 344 783-792
[5]
Bono P(2004)Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression J Clin Oncol 22 1063-1070
[6]
Alanko T(2006)Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy Oncologist 11 318-324
[7]
Kataja V(2005)Antitumor activity of HER-2 inhibitors Cancer Lett 227 9-23
[8]
Asola R(2004)Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase Cancer Res 64 3958-3965
[9]
Utriainen T(2005)Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J Med Chem 48 1107-1131
[10]
Kokko R(2009)A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors Clin Cancer Res 15 2552-2558